2-(1-methylethyl)-11-oxo-11H-pyrido[2,1-b]quinazoline-8-carboxylic acid | 68701-10-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 2-(1-methylethyl)-11-oxo-11H-pyrido[2,1-b]quinazoline-8-carboxylic acid
• 英文别名: 2-(1-methylethyl)-11-oxo-11H-pyrido<2,1-b>quinazoline-8-carboxylic acid；2-isopropyl-11-oxo-11H-pyrido[2,1-b]quinazoline-8-carboxylic acid；2-isopropyl-11-oxo-11H-pyrido[2,1-b]quinazoline-8-carboxylic acid；11-oxo-2-propan-2-ylpyrido[2,1-b]quinazoline-8-carboxylic acid
• CAS: 68701-10-0
• 化学式: C₁₆H₁₄N₂O₃
• 分子量: 282.299
• InChiKey: WOWXQGVIYOJJJX-UHFFFAOYSA-N

物化性质

• 熔点：
  327 °C
• 沸点：
  455.3±55.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  70
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(1-methylethyl)-11-oxo-11H-pyrido[2,1-b]quinazoline-8-carboxylic acid 生成 N-[2-(pyridin-3-yl)ethyl]-2-(1-methylethyl)-11-oxo-11H-pyrido[2,1-b]quinazoline-8-carboxamide
  参考文献：
  名称：

  TILLEY, J. W.

  摘要：

  DOI：
• 作为产物：
  描述：

  6-氯烟酸 、 5-异丙基邻氨基苯甲酸 在 potassium iodide 作用下， 以27%的产率得到2-(1-methylethyl)-11-oxo-11H-pyrido[2,1-b]quinazoline-8-carboxylic acid
  参考文献：
  名称：

  吡啶并[2,1-b]喹唑啉羧酸作为口服活性抗过敏剂。

  摘要：

  通过羰基镍介导的相应溴化物的羧化反应，制备了一系列的8位取代的吡啶并[2,1-]喹唑啉-2-羧酸。这些化合物在大鼠PCA测试中的活性与相应的2-取代的吡啶并[2,1-b]喹唑啉-8-羧酸相当。

  DOI：

  10.1021/jm00175a020

文献信息

• Substituted 11-oxo-11H-pyrido[2,1-b]quinazolines and method of
  申请人：Hoffmann-La Roche Inc.

  公开号：US04348396A1

  公开（公告）日：1982-09-07

  Pyrido[2,1-b]quinazolines of the formulas ##STR1## wherein R.sub.1, R.sub.1 ', R.sub.2, R.sub.2 ', R.sub.3, R.sub.3 ', R.sub.4 and R.sub.10 are as hereinafter set forth, and processes for the preparation thereof, are described. The compounds of formulas I and II are useful as agents in the prevention of allergic reactions.

  本文描述了具有以下结构的吡啶并[2,1-b]喹唑啉的化学式##STR1##其中R.sub.1、R.sub.1'、R.sub.2、R.sub.2'、R.sub.3、R.sub.3'、R.sub.4和R.sub.10如下所述，以及其制备方法。化合物I和II的化学式对于预防过敏反应是有用的。
• N-(heterocyclic alkyl)pyrido[2,1-b]quinazoline-8-carboxamides as orally active antiallergy agents
  作者：Jefferson W. Tilley、Paul Levitan、Joan Lind、Ann F. Welton、Herman J. Crowley、Lawrence D. Tobias、Margaret O'Donnell

  DOI：10.1021/jm00384a031

  日期：1987.1

  4-substituted pyridine or a 1-substituted imidazole ring and the carboxamide nitrogen atom showed the best combination of potencies in the two assays. Several of these compounds were found to be orally active inhibitors of LTE4-induced bronchoconstriction in the guinea pig and LTE4-induced skin wheal formation in the rat. One of the most potent analogues, 2-(1-methyl-ethyl)-N-(1H-imidazol-1-ylbutyl)-11-oxo-11H-pyrido

  评价了一系列N-（杂环烷基）吡啶并[2,1-b]喹唑啉-8-羧酰胺类拮抗豚鼠回肠过敏反应（SRS-A）引起的收缩反应和抑制血栓烷的缓慢反应能力。体外合成酶。结果表明，那些在2-位带有支链烷基部分且在3-或4-取代的吡啶或1之间具有4至6个原子的线性链的吡啶并[2,1-b]喹唑啉-8-甲酰胺在两种测定中，取代的咪唑环和羧酰胺氮原子显示出最佳的效能组合。发现这些化合物中的几种是豚鼠LTE4诱导的支气管收缩和大鼠LTE4诱导的皮肤形成的口服活性抑制剂。最有效的类似物之一，2-（1-甲基-乙基）-N-（1H-咪唑-1-基丁基）-11-氧代-11H-吡啶酮[2，选择1-b]喹唑啉-8-羧酰胺（36）进行广泛的药理研究。已发现该化合物不是LTE4诱导的症状的特异性抑制剂，但通过抑制LTC4，LTD4，PAF诱导的豚鼠支气管痉挛以及LTC4诱导的大鼠和豚鼠中的组胺和皮肤形成而表现出更一般的活性。 ，LT
• Pyrido[2,1-b]quinazoline derivatives useful as agents for treatment of
  申请人：Hoffmann-La Roche Inc.

  公开号：US04551460A1

  公开（公告）日：1985-11-05

  Pyrido[2,1-b]quinazoline derivatives of the formulas ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are as hereinafter set forth, are described. The compounds of formulas I and II are useful as agents for the treatment of allergic conditions as well as for the treatment of vascular disorders involving thrombosis.

  该文描述了化合物的结构公式为##STR1##其中R.sub.1、R.sub.2和R.sub.3如下所述的吡啶[2,1-b]喹唑啉衍生物。公式I和II的化合物可用作治疗过敏症状的药物，也可用于治疗涉及血栓形成的血管疾病。
• Antagonists of slow-reacting substance of anaphylaxis. 1. Pyrido[2,1-b]quinazolinecarboxylic acid derivatives
  作者：Jefferson W. Tilley、Paul Levitan、Ann F. Welton、Herman J. Crowley

  DOI：10.1021/jm00365a016

  日期：1983.11

  Members of a series of basic amide and ester derivatives of 2-substituted pyrido[2,1-b]quinazoline-8-carboxylic acids were prepared and evaluated for their ability to prevent slow-reacting substance of anaphylaxis (SRS-A) induced contractions of guinea pig ilea. The results indicate that the presence of a branched-chain alkyl group in the 2-position and a sterically demanding substituted aminoethyl carboxylate or carboxamide in the 8-position give optimal in vitro activity. The phenylpiperazine 25 was further found to block SRS-A-related symptomatology after intravenous administration in two animal models.
• Pyrido[2,1-b]quinazolinecarboxamide derivatives as platelet activating factor antagonists
  作者：Jefferson W. Tilley、Barbara Burghardt、Charles Burghardt、Thomas F. Mowles、Franz Josef Leinweber、Larry Klevans、Richard Young、Gerry Hirkaler、Kenneth Fahrenholtz

  DOI：10.1021/jm00397a034

  日期：1988.2

  A series of N-[(heteroaryl)alkyl]pyrido[2,1-b]quinazolines were evaluated for their ability to inhibit the binding of radiolabeled platelet activating factor (PAF) to its receptor on dog platelets. The most potent compounds in this series were found to be pyrido[2,1-b]quinazoline-8-carboxamides possessing a four- or six-carbon chain between the carboxamide nitrogen atom and a 3-pyridinyl or 5-pyrimidinyl moiety. Since earlier metabolism studies with pyridoquinazolinecarboxamides suggest that the carboxamide moiety is labile to hydrolysis in vivo, attempts were made to find isosteric replacements for this group. The substitutions examined led to a loss of activity; however, insertion of a methyl group on the carbon atom alpha to the carboxamide nitrogen led to an enantioselective enhancement of potency. (R)-2-(1-Methylethyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-11-oxo-11H- pyrido[2,1-b]quinazoline-8-carboxamide (34) was more potent than the corresponding S enantiomer in the PAF binding assay and was also shown to be more resistant to degradation by amidases present in whole liver homogenates obtained from guinea pig, dog, and squirrel monkey. The corresponding rac-2-(1-methylethyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-11-oxo-11H- pyrido[2,1-b]quinazoline-8-carboxamide (33) was found to inhibit transient PAF-induced thrombocytopenia and decreases in blood pressure in guinea pigs after intravenous or oral administration and to have a duration of action of greater than 5 h after an oral dose of 200 mg/kg. Compound 33 thus represents the prototype of a new class of orally active PAF antagonists.